Table 1.
In vivo protocol and experimental groups
| Groups | 1. dose | 2. dose | 3. dose |
|---|---|---|---|
| Subcutaneous | Intravenous | Intravenous | |
| Control | NaCl (0.9 %) | NaCl (0.9 %) | NaCl (0.9 %) |
| AT | NaCl (0.9 %) | NaCl (0.9 %) | AT (250 IU/kg) |
| TrypAT | NaCl (0.9 %) | NaCl (0.9 %) | TrypAT (250 IU/kg) |
| Indo | indo (5 mg/kg) | NaCl (0.9 %) | NaCl (0.9 %) |
| Indo + AT | indo (5 mg/kg) | NaCl (0.9 %) | AT (250 IU/kg) |
| Heparin | NaCl (0.9 %) | heparin (100 IU/kg) | NaCl (0.9 %) |
| Heparin + AT | NaCl (0.9 %) | heparin (100 IU/kg) | AT (250 IU/kg) |
Flow chart displaying the in vivo protocol for the different experimental groups in C57Bl/6J mice. Before intravital fluorescence microscopy (IVM) and thrombosis induction (TI), anesthetized mice received different applications of the respective substances
AT antithrombin, Indo indomethacin, TrypAT tryptophane49-modified AT